ERBB2 and breast carcinoma: This retrospective study analyzed a large cohort of patients treated with neoadjuvant chemotherapy at a single-center certified breast cancer center in Germany, with up to 20 years of follow-up, to evaluate the differences in survival parameters for breast cancer patients with HER2-0 and HER2-low-positive tumors.